retatrutide new zealand sodium salt | CAS 2381089-83-2 - Adipogen Life Sciences Retatrutide, a GIP, GLP-1 and

How do they compare to true GLP-1 medications

has a lot to like

The medicine has progressed through Phase 2 clinical trials , where participants achieved: Dose-dependent weight loss of up to 24.2% after 48 weeks at higher doses 83% of participants at the maximum 12 mg dose losing 15% or more of their body weight All patients taking 8 mg or above are achieving at least 5% weight loss Larger Phase 3 trials are now underway to confirm these findings in broader, more diverse patient groups and to build longer-term safety data

NAFLD is common among individuals with obesity, potentially leading to serious complications if untreated

Wall Street already wrote the ending My disclosure matters most here: I own Lilly shares, so discount accordingly

Balancing GLP-1 Clinical Benefits with Financial Sustainability Pain Point : Plan sponsors are challenged to provide access to promising new medications while also controlling costs for both the plan and employees